Aldeyra Therapeutics SEC filings document a biotechnology issuer focused on investigational therapies for immune-mediated diseases and formal disclosures tied to its RASP modulator pipeline. Recent 8-K reports furnish press releases and corporate presentations covering reproxalap regulatory review, clinical and preclinical program updates, pipeline prioritization, and FDA-related disclosures for dry eye disease.
The filing record also covers governance and capital-structure matters, including definitive proxy materials for annual meeting proposals and director elections, board-transition disclosures, and the payoff and termination of the Hercules Credit Facility. These filings group Aldeyra's public-company record around operating updates, risk and forward-looking-statement disclosures, stockholder voting matters, and financing arrangements.
Aldeyra Therapeutics director Neal Walker received two new stock option grants. On the grant date, he was awarded options for 3,318 and 70,000 shares of common stock at an exercise price of $1.72 per share. Each grant becomes fully exercisable one year after grant, contingent on his continued Board and Compensation Committee service.
Aldeyra Therapeutics director Ben Bronstein received three stock option awards, each covering rights to buy common stock at an exercise price of $1.72 per share. The grants cover 4,977, 5,309, and 70,000 underlying shares, respectively, and are reported as compensation-related acquisitions rather than market purchases.
According to the filing, each option becomes exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided Bronstein continues serving on the Board of Directors and, for two grants, on the Nominating/Corporate Governance and Audit Committees through the applicable vesting dates. All options are scheduled to expire on June 8, 2036 if not exercised.
Aldeyra Therapeutics, Inc. director Darlene M. Deptula‑Hicks received two stock option grants to acquire common stock at an exercise price of $1.72 per share.
One option for 9,756 shares vests in equal annual installments over three years after June 9, 2026. A second option for 84,557 shares becomes exercisable for all shares on the one‑year anniversary of the grant date if she continues serving on the Audit Committee. Both options expire on June 8, 2036.
Aldeyra Therapeutics, Inc. director Darlene M. Deptula-Hicks filed an initial Form 3, which is a statement of beneficial ownership for insiders. This filing does not report any stock transactions or option exercises; it simply establishes her status as a reporting person at the company.
Aldeyra Therapeutics, Inc. appointed Darlene Deptula-Hicks as a Class III director and Chair of the audit committee following its 2026 annual stockholder meeting. She is considered independent and qualifies as an audit committee financial expert under SEC and Nasdaq rules.
As a new non-employee director, she received a stock option for 94,313 common shares that vests over three years, plus annual cash fees for board and audit chair service and eligibility for additional annual option grants. Stockholders elected Todd C. Brady, M.D., Ph.D., ratified BDO USA, P.C. as auditor for 2026, and approved executive compensation on an advisory basis.
Aldeyra Therapeutics, Inc. President and CEO Todd C. Brady reported an open-market purchase of common stock. He bought 250,000 shares of Aldeyra common stock at a weighted average price of $1.6738 per share in transactions on June 3, 2026. Following this purchase, he directly owns 1,721,298 shares of Aldeyra common stock. The footnote explains that the shares were acquired in multiple trades at prices ranging from $1.64 to $1.70 per share.
Aldeyra Therapeutics, Inc. amendment to a Schedule 13G discloses that Perceptive Advisors LLC, Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd. report 0% beneficial ownership of Aldeyra Therapeutics common stock (CUSIP 01438T106). The filing states each Reporting Person holds zero shares and confirms ownership of 5% or less of the class.
Aldeyra Therapeutics filed an update highlighting FDA feedback on its lead RASP modulator reproxalap, an AbbVie option agreement, and progress across its immunology pipeline. The FDA issued a Complete Response Letter for reproxalap in dry eye disease, citing lack of substantial efficacy evidence and inconsistent trial results, though no safety or manufacturing issues were identified and a Type A meeting is expected in the second quarter of 2026.
The company argues pooled trial data show a clear pattern of reproxalap superiority over vehicle and notes that five of nine efficacy trials met all primary endpoints, with P values below 0.05 for nine of 14 endpoints. Aldeyra also emphasizes strong Phase 3 data in allergic conjunctivitis and multiple early‑stage RASP modulators, rare retinal disease candidate ADX‑2191, and other programs. As of 12/31/2026, cash, cash equivalents, and marketable securities were $70, which Aldeyra believes will be sufficient to fund the company into 2028.